Polpharma Pharmaceutical Works - API Manufacturer

drukuj

Toll & custom manufacturing   

Our cGMP capacity combined with a short development time and competitive pricing make us a natural first choice for pharmaceutical companies interested in outsourcing their manufacturing activities.

 


What can we offer our partners?

  • Wide reaction classes in FDA approved facilities
  • State-of-the-art technology and best design processes and practices
  • Low cost, highly skilled workforce
  • Own R&D resources including pilot plant and wide cooperation with external research and academic institutions and laboratories



What makes us different from other competitors?

  • Full scale and vertical integration of processes from R&D and the GMP Pilot plant, scaling up to manufacturing
  • Highly skilled workforce with an ever increasing proportion of university graduates at a relatively low cost
  • Low cost environment thanks to the competitive labor cost and location of the entire manufacturing site in an economic zone

 

Legislation benefits

 

Legislation                                               Benefit

 

Product patent law introduced in 1993 with grandfathering previous process patent status.
Molecules with product patents granted up to 1993 do not come under patent protection. It enables us to develop alternative processes for the synthesis of attractive compounds.
The Bolar-Roche provision.
Development work on patented products can start prior to the patent expiration date.
The SPC regime applies to products that were protected by a valid patent on the date of Poland's accession to the EU and obtained their first marketing authorization in Poland or the EU after January 1, 2000.
Shorter patent protection period for APIs authorized before January 1, 2000.
The preferential intellectual property status is an opportunity for the development of alternative processes for the synthesis of commercially attractive compounds for sales in countries such as Poland, which recently adopted the product patent.

Latest news

CEP for Baclofen available

Monday, 02-01-2012
Polpharma has been granted Certificate of Suitability (CEP) by the European Directorate for the Quality of...

Polpharma – the most innovative company in Poland

Friday, 20-05-2011
Polpharma ranked first as the most innovative company in Poland, in a research study run by the Institute...

Polpharma has inaugurated a new state of the art 300 sq.m. Process Development Labs complex

Friday, 08-10-2010
Polpharma has inaugurated a new state of the art 300 sq.m. Process Development Labs complex for the...

Co-operation between Polpharma and RPG Life Sciences

Tuesday, 05-10-2010
RPGLS and Polpharma announced their co-operation in the development and manufacture of Active...
© POLPHARMA S.A. All rights reserved.
Realizacja: Ideo